APREMILAST
Information current as at: 1 May 2025
Submission Details
- Brand name:
-
- Otezla®
- Pharmaceutical company:
- Amgen Australia Pty Ltd
- Condition/indication:
(therapeutic use) -
- Plaque psoriasis
- PBAC Submission type:
- New listing (Minor)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – July 2020
- Related medicines:
- --
Progress Details
-
Submission received for: - July 2020 PBAC meeting
-
Opportunity for consumer comment: - Open 29/04/2020 and close 10/06/2020 (see PBS Website)
-
PBAC meeting: - Held on 08/07/2020
-
Lodgement of required documentation: - 11/08/2020
-
Acceptance of complete documentation:
- Accepted
-
Agreement to listing arrangements: - Commenced on 02/09/2020
-
Status:
- Finalised
-
Government processes: - Commenced on 06/11/2020
-
Medicine listed on the PBS: - 01/01/2021 (see PBS schedule)
Case ID: a166
Page last updated: 31 October 2024